Max Wolff, Dr. rer. nat.
Associate Researcher, Central Institute of Mental Health, Mannheim, & Charité Berlin
Max Wolff is a psychologist and psychotherapist, currently a research associate at the Central Institute of Mental Health in Mannheim and at Charité-Universitätsmedizin Berlin, Germany. His research explores the psychotherapeutic mechanisms of psychedelic therapy and seeks to build bridges between psychedelic science and psychotherapy research. He has worked as a researcher and therapist in several clinical trials investigating psychedelic substances for the treatment of mental disorders, including the EPIsoDE trial, a phase IIb study assessing the safety and efficacy of psilocybin for treatment-resistant depression at the Central Institute of Mental Health and Charité. Beyond his research, Max is committed to advancing psychedelic therapy training. He led the development of the MIND Foundation’s Augmented Psychotherapy Training (APT) program, a competency-based international training for psychotherapists, psychiatrists, and other mental health professionals.
Conflicts of Interest: Max Wolff is a shareholder of OVID Tagesklinik GmbH.